Soligenix Receives $840,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received approximately $840,000, net of transaction costs, in non-dilutive
source https://finance.yahoo.com/news/soligenix-receives-840-000-non-110000663.html
Comments
Post a Comment